IBSRELA (tenapanor hydrochloride) by Ardelyx is sodium/hydrogen exchanger 3 (nhe3), an antiporter expressed on the apical surface of the small intestine and colon primarily responsible for the absorption of dietary sodium. Approved for irritable bowel syndrome with constipation (ibs-c) in adults. First approved in 2019.
Drug data last refreshed 19h ago · AI intelligence enriched 3w ago
IBSRELA (tenapanor hydrochloride) is an oral tablet approved in September 2019 for irritable bowel syndrome with constipation (IBS-C) in adults. It works by inhibiting the sodium/hydrogen exchanger 3 (NHE3) on the intestinal epithelium, reducing sodium absorption and increasing water secretion into the intestinal lumen. This mechanism accelerates intestinal transit, softens stool consistency, and reduces visceral hypersensitivity and abdominal pain. IBSRELA represents a novel mechanism class in the IBS-C treatment landscape, offering a targeted approach distinct from traditional osmotic or secretory laxatives.
sodium/hydrogen exchanger 3 (NHE3), an antiporter expressed on the apical surface of the small intestine and colon primarily responsible for the absorption of dietary sodium. In vitro and animal studies indicate its major metabolite, M1, is not active against NHE3. By inhibiting NHE3 on the apical…
Worked on IBSRELA at Ardelyx? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
IBSRELA creates opportunities for brand managers focused on specialty/niche gastroenterology markets, medical science liaisons (MSLs) targeting gastroenterologists and primary care physicians, and field sales teams in the IBS-C space. Key skills include GI disease knowledge, understanding of NHE3 mechanism, and ability to articulate differentiation versus symptomatic therapies. Currently, zero open positions are linked to this product in the career intelligence database.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/mo